The agreement between ALK-Abello and Schering-Plough on immunotherapy compounds welcomes the first tablet-based vaccine against grass pollen allergy on the global market. While immunotherapy is increasingly popular in Europe, the US remains a novice, offering great potential for ALK-Abellos Grazax. Lisette Oversteegen, respiratory analyst at Datamonitor, investigates… === Putting the NEWS back into NEWSgroups, It's Just One of Today's Top 10 Anticholinergics News Reports: http://www.ng2000.com/fw.php?tp=anticholinergics